Efficacy and safety of odanacatib in the treatment of postmenopausal women with osteoporosis: a meta-analysis.
Humans
Female
Osteoporosis, Postmenopausal
/ drug therapy
Bone Density
/ drug effects
Treatment Outcome
Biphenyl Compounds
/ therapeutic use
Bone Density Conservation Agents
/ therapeutic use
Randomized Controlled Trials as Topic
Biomarkers
/ blood
Cathepsin K
/ antagonists & inhibitors
Middle Aged
Aged
Bone Remodeling
/ drug effects
Efficacy
Odanacatib
Postmenopausal osteoporosis
Safety
Journal
Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112
Informations de publication
Date de publication:
29 Aug 2024
29 Aug 2024
Historique:
received:
04
07
2024
accepted:
19
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
Osteoporosis, a systemic skeletal disease, seriously affects the quality of life in postmenopausal women. As one type of cathepsin K (CatK) inhibitor, odanacatib (ODN) is a fresh medication for osteoporosis. Considering the potential of ODN, we further examined the effect and safety of ODN for postmenopausal osteoporosis (PMOP) with a meta-analysis. PubMed, EMBASE, Cochrane Library, and Web of Science were searched for eligible studies from inception to December 29th, 2023. After that, we conducted a comprehensive meta-analysis following PRISMA guidelines. Risk of bias was meticulously investigated with the Cochrane Collaboration's tool. Efficacy was assessed with bone mineral density (BMD) at different sites (lumbar spine, trochanter, radius, femoral neck) and biomarkers of bone turnover (P1NP, uNTx/Cr, s-CTx, BSAP). Safety was evaluated by analyzing total, serious, other, and skin adverse events (AEs). Four random clinical trials (RCTs) were involved in our research. All trials were rated as having high quality and met the eligibility criteria. In the current research, ODN was found to elevate BMD at lumbar spine, femoral neck, total hip, trochanter and forearm, while it decreased the levels of serum C-telopeptides of type I collagen (s-CTx) as well as urinary N-telopeptide/creatinine ratio (uNTx/Cr). No significant differences were observed in AEs between the ODN group and the control group. ODN is a promising alternative for the treatment of PMOP on account of its excellent efficacy and credible safety. Unclear links between ODN and cardiovascular AEs require further research to clarify.
Sections du résumé
BACKGROUND
BACKGROUND
Osteoporosis, a systemic skeletal disease, seriously affects the quality of life in postmenopausal women. As one type of cathepsin K (CatK) inhibitor, odanacatib (ODN) is a fresh medication for osteoporosis. Considering the potential of ODN, we further examined the effect and safety of ODN for postmenopausal osteoporosis (PMOP) with a meta-analysis.
METHODS
METHODS
PubMed, EMBASE, Cochrane Library, and Web of Science were searched for eligible studies from inception to December 29th, 2023. After that, we conducted a comprehensive meta-analysis following PRISMA guidelines. Risk of bias was meticulously investigated with the Cochrane Collaboration's tool. Efficacy was assessed with bone mineral density (BMD) at different sites (lumbar spine, trochanter, radius, femoral neck) and biomarkers of bone turnover (P1NP, uNTx/Cr, s-CTx, BSAP). Safety was evaluated by analyzing total, serious, other, and skin adverse events (AEs).
RESULTS
RESULTS
Four random clinical trials (RCTs) were involved in our research. All trials were rated as having high quality and met the eligibility criteria. In the current research, ODN was found to elevate BMD at lumbar spine, femoral neck, total hip, trochanter and forearm, while it decreased the levels of serum C-telopeptides of type I collagen (s-CTx) as well as urinary N-telopeptide/creatinine ratio (uNTx/Cr). No significant differences were observed in AEs between the ODN group and the control group.
CONCLUSIONS
CONCLUSIONS
ODN is a promising alternative for the treatment of PMOP on account of its excellent efficacy and credible safety. Unclear links between ODN and cardiovascular AEs require further research to clarify.
Identifiants
pubmed: 39210429
doi: 10.1186/s13018-024-05008-z
pii: 10.1186/s13018-024-05008-z
doi:
Substances chimiques
odanacatib
N673F6W2VH
Biphenyl Compounds
0
Bone Density Conservation Agents
0
Biomarkers
0
Cathepsin K
EC 3.4.22.38
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
521Subventions
Organisme : National Key Research and Development Program of China
ID : 2023YFC3603404
Organisme : National Natural Science Foundation of China
ID : 82072506
Organisme : Hunan Provincial Science Fund for Distinguished Young Scholars
ID : 2024JJ2089
Organisme : Hunan Young Talents of Science and Technology
ID : 2021RC3025
Organisme : Provincial Clinical Medical Technology Innovation Project of Hunan
ID : 2023SK2024
Organisme : National Natural Science Foundation of Hunan Province
ID : 2023JJ30949
Organisme : National Clinical Research Center for Geriatric Disorders, Xiangya Hospital
ID : 2021KFJJ02
Informations de copyright
© 2024. The Author(s).
Références
Management of Postmenopausal Osteoporosis: ACOG Clinical Practice Guideline No. Obstet Gynecol. 2022;139(4):698–717. https://doi.org/10.1097/aog.0000000000004730 . 2.
doi: 10.1097/aog.0000000000004730
Cauley JA. Public health impact of osteoporosis. J Gerontol Biol Sci Med Sci. 2013;68(10):1243–51. https://doi.org/10.1093/gerona/glt093 .
doi: 10.1093/gerona/glt093
Wade SW, Strader C, Fitzpatrick LA, Anthony MS, O’Malley CD. Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporos. 2014;9:182. https://doi.org/10.1007/s11657-014-0182-3 .
doi: 10.1007/s11657-014-0182-3
pubmed: 24847682
Chen P, Li Z, Hu Y. Prevalence of osteoporosis in China: a meta-analysis and systematic review. BMC Public Health. 2016;16(1):1039. https://doi.org/10.1186/s12889-016-3712-7 .
doi: 10.1186/s12889-016-3712-7
pubmed: 27716144
pmcid: 5048652
Zeng Q, Li N, Wang Q, Feng J, Sun D, Zhang Q, et al. The prevalence of osteoporosis in China, a Nationwide, Multicenter DXA Survey. J Bone Min Res. 2019;34(10):1789–97. https://doi.org/10.1002/jbmr.3757 .
doi: 10.1002/jbmr.3757
Management of osteoporosis in postmenopausal women. 2010 position statement of the North American Menopause Society. Menopause. 2010;17(1):25–54. https://doi.org/10.1097/gme.0b013e3181c617e6 . quiz 5–6.
doi: 10.1097/gme.0b013e3181c617e6
Management of osteoporosis in. Postmenopausal women: the 2021 position statement of the North American Menopause Society. Menopause. 2021;28(9):973–97. https://doi.org/10.1097/gme.0000000000001831 .
doi: 10.1097/gme.0000000000001831
Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–62. https://doi.org/10.1056/NEJMcp1513724 .
doi: 10.1056/NEJMcp1513724
pubmed: 26789873
Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet (London England). 2011;377(9773):1276–87. https://doi.org/10.1016/s0140-6736(10)62349-5 .
doi: 10.1016/s0140-6736(10)62349-5
pubmed: 21450337
Looker AC, Sarafrazi Isfahani N, Fan B, Shepherd JA. Trends in osteoporosis and low bone mass in older US adults, 2005–2006 through 2013–2014. Osteoporos Int. 2017;28(6):1979–88. https://doi.org/10.1007/s00198-017-3996-1 .
doi: 10.1007/s00198-017-3996-1
pubmed: 28315954
pmcid: 7891684
Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;1Cd001155. https://doi.org/10.1002/14651858.CD001155.pub2 .
Wells GA, Hsieh SC, Zheng C, Peterson J, Tugwell P, Liu W. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2022;5(5):Cd004523. https://doi.org/10.1002/14651858.CD004523.pub4 .
doi: 10.1002/14651858.CD004523.pub4
pubmed: 35502787
Reginster J, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int. 2019;30(7):1465–73. https://doi.org/10.1007/s00198-019-04947-2 .
doi: 10.1007/s00198-019-04947-2
pubmed: 30953114
pmcid: 6614166
Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, et al. Efficacy of pharmacological therapies for the Prevention of fractures in Postmenopausal women: A Network Meta-Analysis. J Clin Endocrinol Metab. 2019;104(5):1623–30. https://doi.org/10.1210/jc.2019-00192 .
doi: 10.1210/jc.2019-00192
pubmed: 30907957
Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, et al. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int. 2013;24(1):209–17. https://doi.org/10.1007/s00198-012-2068-9 .
doi: 10.1007/s00198-012-2068-9
pubmed: 22832638
Liu GF, Wang ZQ, Liu L, Zhang BT, Miao YY, Yu SN. A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis. J Cell Biochem. 2018;119(6):4469–81. https://doi.org/10.1002/jcb.26550 .
doi: 10.1002/jcb.26550
pubmed: 29227547
Messori A, Fadda V, Maratea D, Trippoli S, Marinai C. Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods. J Endocrinol Invest. 2014;37(8):769–73. https://doi.org/10.1007/s40618-014-0124-3 .
doi: 10.1007/s40618-014-0124-3
pubmed: 25008458
Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008;18(3):923–8. https://doi.org/10.1016/j.bmcl.2007.12.047 .
doi: 10.1016/j.bmcl.2007.12.047
pubmed: 18226527
Pérez-Castrillón P JL, Pinacho F, De Luis D, Lopez-Menendez M, Dueñas Laita A. Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women. J Osteoporos. 2010;2010. https://doi.org/10.4061/2010/401581 .
Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Min Res. 2011;26(2):242–51. https://doi.org/10.1002/jbmr.212 .
doi: 10.1002/jbmr.212
Suvan J, Leira Y, Moreno Sancho FM, Graziani F, Derks J, Tomasi C. Subgingival instrumentation for treatment of periodontitis. A systematic review. J Clin Periodontol. 2020;47(Suppl 22):155–75. https://doi.org/10.1111/jcpe.13245 .
doi: 10.1111/jcpe.13245
pubmed: 31889320
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928 .
doi: 10.1136/bmj.d5928
pubmed: 22008217
pmcid: 3196245
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557 .
doi: 10.1136/bmj.327.7414.557
pubmed: 12958120
pmcid: 192859
Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Min Res. 2010;25(5):937–47. https://doi.org/10.1359/jbmr.091035 .
doi: 10.1359/jbmr.091035
Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res. 2011;26(2):242–51. https://doi.org/10.1002/jbmr.212 .
doi: 10.1002/jbmr.212
pubmed: 20740685
Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res. 2012;27(11):2251–8. https://doi.org/10.1002/jbmr.1695 .
doi: 10.1002/jbmr.1695
pubmed: 22777865
Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, et al. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2013;98(12):4727–35. https://doi.org/10.1210/jc.2013-2020 .
doi: 10.1210/jc.2013-2020
pubmed: 24064689
Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab. 2013;98(2):571–80. https://doi.org/10.1210/jc.2012-2972 .
doi: 10.1210/jc.2012-2972
pubmed: 23337728
Cheung AM, Majumdar S, Brixen K, Chapurlat R, Fuerst T, Engelke K, et al. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength. J Bone Miner Res. 2014;29(8):1786–94. https://doi.org/10.1002/jbmr.2194 .
doi: 10.1002/jbmr.2194
pubmed: 24643905
Engelke K, Fuerst T, Dardzinski B, Kornak J, Ather S, Genant HK, et al. Odanacatib Treatment affects trabecular and cortical bone in the femur of Postmenopausal women: results of a two-year placebo-controlled trial. J Bone Miner Res. 2015;30(1):30–8. https://doi.org/10.1002/jbmr.2292 .
doi: 10.1002/jbmr.2292
pubmed: 24898537
Rizzoli R, Benhamou CL, Halse J, Miller PD, Reid IR, Rodríguez Portales JA, et al. Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study. Osteoporos Int. 2016;27(6):2099–107. https://doi.org/10.1007/s00198-016-3503-0 .
doi: 10.1007/s00198-016-3503-0
pubmed: 26879200
McClung MR, O’Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, et al. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT extension study. Lancet Diabetes Endocrinol. 2019;7(12):899–911. https://doi.org/10.1016/s2213-8587(19)30346-8 .
doi: 10.1016/s2213-8587(19)30346-8
pubmed: 31676222
Recker R, Dempster D, Langdahl B, Giezek H, Clark S, Ellis G, et al. Effects of Odanacatib on Bone structure and quality in Postmenopausal Women with osteoporosis: 5-Year Data from the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its extension. J Bone Miner Res. 2020;35(7):1289–99. https://doi.org/10.1002/jbmr.3994 .
doi: 10.1002/jbmr.3994
pubmed: 32119749
Papapoulos S, Bone H, Cosman F, Dempster DW, McClung MR, Nakamura T, et al. Incidence of hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women with osteoporosis in the phase 3 Long-Term Odanacatib Fracture Trial. J Bone Miner Res. 2021;36(7):1225–34. https://doi.org/10.1002/jbmr.4284 .
doi: 10.1002/jbmr.4284
pubmed: 33724542
Feng S, Luo Z, Liu D. Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis. J Bone Min Metab. 2015;33(4):448–54. https://doi.org/10.1007/s00774-014-0609-3 .
doi: 10.1007/s00774-014-0609-3
Gajic-Veljanoski O, Tomlinson G, Srighanthan J, Adachi JD, Josse R, Brown JP, et al. Effect of odanacatib on BMD and fractures: estimates from bayesian univariate and bivariate meta-analyses. J Clin Endocrinol Metab. 2014;99(9):3070–9. https://doi.org/10.1210/jc.2014-1162 .
doi: 10.1210/jc.2014-1162
pubmed: 24823462
Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP, Cathepsin K. Its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011;7(8):447–56. https://doi.org/10.1038/nrrheum.2011.77 .
doi: 10.1038/nrrheum.2011.77
pubmed: 21670768
Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5(11):898–907. https://doi.org/10.1016/s2213-8587(17)30188-2 .
doi: 10.1016/s2213-8587(17)30188-2
pubmed: 28689769
pmcid: 5798872
Masarachia PJ, Pennypacker BL, Pickarski M, Scott KR, Wesolowski GA, Smith SY, et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Min Res. 2012;27(3):509–23. https://doi.org/10.1002/jbmr.1475 .
doi: 10.1002/jbmr.1475
Chen R, Chen C, Geng B, Yang C, Xiao H, Yang F, et al. Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis. Arch Osteoporos. 2023;18(1):67. https://doi.org/10.1007/s11657-023-01261-7 .
doi: 10.1007/s11657-023-01261-7
pubmed: 37169994
Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Min Res. 2012;27(11):2251–8. https://doi.org/10.1002/jbmr.1695 .
doi: 10.1002/jbmr.1695
Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol. 2008;59(1):125–9. https://doi.org/10.1016/j.jaad.2008.03.009 .
doi: 10.1016/j.jaad.2008.03.009
pubmed: 18410981
Rünger TM, Adami S, Benhamou CL, Czerwiński E, Farrerons J, Kendler DL, et al. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol. 2012;66(3):e89–96. https://doi.org/10.1016/j.jaad.2010.11.033 .
doi: 10.1016/j.jaad.2010.11.033
pubmed: 21571394
Saag KG, de Villiers TJ, Alexandersen P, Jacobe H, Kovarik C, Werth VP, et al. Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis. J Am Acad Dermatol. 2021;84(4):1113–9. https://doi.org/10.1016/j.jaad.2020.06.036 .
doi: 10.1016/j.jaad.2020.06.036
pubmed: 32553680